International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7847904
Original Article
Study of Clinical Profile of Dilated Cardiomyopathy
 ,
 ,
Published
April 20, 2023
Abstract
BACKGROUND: Cardiomyopathy is a disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body. Cardiomyopathy can lead to heart failure. The main types of cardiomyopathies include dilated, hypertrophic and restrictive cardiomyopathy. Treatment — which might include medications, surgically implanted devices, heart surgery or, in severe cases, a heart transplant — depends on the type of cardiomyopathy and how serious it is[1]. Dilated Cardiomyopathy (DCM) is a disease of the heart muscle characterized by enlargement and dilation of one or both of the ventricles along with impaired contractility defined as left ventricular ejection fraction (LVEF) less than 40%. Patients have systolic dysfunction and may or may not have overt symptoms of heart failure. A previous prominent classification of cardiomyopathies (1995) was represented in a very brief document under the auspices of the World Health Organization (WHO)[2], The natural history of DCM remains incompletely understood. This is because this diagnosis clearly contains a variety of causes and patients have highly variable presentations. The prognosis of DCM may be much more variable than previously appreciated. Several features of the clinical presentation may be valuable in predicting patient outcome. In view of high prevalence of heart failure and also lack of data on dilated cardiomyopathy this study was undertaken. The ECG and echocardiography were also evaluated in the present study. METHODS - A cross sectional study on 60 patients with dilated cardiomyopathy was conducted in a teaching hospital in Vadodara, Gujarat. RESULTS - In our study the most common type of dilated cardiomyopathy was idiopathic dilated cardiomyopathy being present in 60% of our patients, followed by alcoholic cardiomyopathy seen in 15 %. Diabetic cardiomyopathy was found to be the third most common type seen in 13.3% of patients while Peripartum cardiomyopathy were seen in 11.6%. n our study 32 % of patients had anemia, most of the patients had mild anemia (i.e., Hb between 8.5 – 11 gm %). In a study done by A. Justin et al anemia was found in 27% of patients with congestive heart failure. The prevalence of anemia in our study is similar. Anemia is known to be associated with adverse outcome in patients with heart failure. Among alcoholic's alcohol plays a significant etiological role (p value <0.0001). Biventricular failure was present in 70% of patients and isolated LV failure was seen in 27%, 3% patient in our study had RV failure. The cardio thoracic ratio was more than 0.7 in 22%, it was between 0.6 to 0.7(moderate) in 43% and 35% of patients had mild cardiomegaly i.e., between 0.5 to 0.6 CONCLUSION- The major cause of dilated cardiomyopathy in our study was found to be idiopathic followed by alcoholic, diabetic and peripartum cardiomyopathy. The most common clinical presentation is biventricular failure. Almost all patients showed cardiomegaly in chest x-ray.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1402 Views
389 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved